01:23:58 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-07-30 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2023-01-18 12:30:00

Lund, Jan 18, 2023 —Ziccum AB CEO Ann Gidner will present LaminarPace, the company’s unique mass transfer drying methodology, at the mRNA-based Therapeutics Summit in Berlin 24 – 26 January. It is the leading European event for mRNA innovation expertise in Europe. On October 24, 2022 Ziccum announced that it had generated proof of successful nebulization and drying of vaccine lipid nanoparticles (LNP) in the latest stage of its ongoing in-house mRNA project. mRNA is the core strategic priority for the company.

On January 25th, Ziccum CEO Ann Gidner will present LaminarPace to an audience of senior Pharmaceutical industry decision makers, scientists and key opinion leaders in Berlin at an event described as ‘the most comprehensive, industry-leading meeting for mRNA experts in Europe’.

mRNA in lipid nanoparticle (LNP) formulation is the break-through innovation that enabled mass-vaccination against Covid-19 around the globe. mRNA research and investment continues accelerating at great speed, and for Ziccum is the top strategic priority. LaminarPace, the company’s ambient drying methodology based on the principle of mass transfer, efficiently turns liquid biopharmaceuticals into thermostable dry powders. In October 2022, Ziccum announced that it had nebulized and dried lipid nanoparticles (LNPs) in the latest stage of its proprietary mRNA project.

Ziccum’s presentation is titled LaminarPace: a novel unit operation successfully drying mRNA/LNP by mass transfer. It will cover LaminarPace’s unique ambient drying methodology based on the principle of mass transfer and how it dries liquid biopharmaceuticals into thermostable dry powders – a normally very challenging step - thanks to greatly reduced stress factors in the unique process.

It will describe how the well-defined dry powder delivered by LaminarPace can be reconstituted or used for novel administration routes, and how the system is being developed by Ziccum as a Pharmaceutical unit of production.

CEO Ann Gidner: “Our capabilities within mRNA could be a game changer for this innovative industry. Mass transfer drying, avoiding the difficulties of existing technologies and achieving thermostable formulations, could open up many new possibilities and opportunities. We look forward to sharing ideas with our colleagues in the field at this exciting event.”

Book a meeting
with CEO Ann Gidner or Scientific Director Fabrice Rose
at the event here.